Skip to main content
Top
Published in: Annals of Surgical Oncology 12/2021

01-11-2021 | Magnetic Resonance Imaging | Breast Oncology

Prediction of Pathologic Complete Response in Breast Cancer Patients Comparing Magnetic Resonance Imaging with Ultrasound in Neoadjuvant Setting

Authors: Frederik Knude Palshof, Charlotte Lanng, Niels Kroman, Cemil Benian, Ilse Vejborg, Anne Bak, Maj-Lis Talman, Eva Balslev, Tove Filtenborg Tvedskov

Published in: Annals of Surgical Oncology | Issue 12/2021

Login to get access

Abstract

Background

Some subgroups of breast cancer patients receiving neoadjuvant chemotherapy (NACT) show high rates of pathologic complete response (pCR) in the breast, proposing the possibility of omitting surgery. Prediction of pCR is dependent on accurate imaging methods. This study investigated whether magnetic resonance imaging (MRI) is better than ultrasound (US) in predicting pCR in breast cancer patients receiving NACT.

Methods

This institutional, retrospective study enrolled breast cancer patients receiving NACT who were examined by either MRI or combined US and mammography before surgery from 2016 to 2019. Imaging findings were compared with pathologic response evaluation of the tumor. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy for prediction of pCR were calculated and compared between MRI and US.

Results

Among 307 patients, 151 were examined by MRI and 156 by US. In the MRI group, 37 patients (24.5 %) had a pCR compared with 51 patients (32.7 %) in the US group. Radiologic complete response (rCR) was found in 35 patients (23.2 %) in the MRI group and 26 patients (16.7 %) in the US group. In the MRI and US groups, estimates were calculated respectively for sensitivity (87.7 % vs 91.4 %), specificity (56.8 % vs 33.3 %), PPV (86.2 % vs 73.8 %), NPV (60.0 % vs 65.4 %), and accuracy (80.1 % vs 72.4 %).

Conclusions

In predicting pCR, MRI was more specific than US, but not sufficiently specific enough to be a valid predictor of pCR for omission of surgery. As an imaging method, MRI should be preferred when future studies investigating prediction of pCR in NACT patients are planned.
Appendix
Available only for authorised users
Literature
5.
go back to reference Chen M, Zhan WW, Han BS, et al. Accuracy of physical examination, ultrasonography, and magnetic resonance imaging in predicting response to neo-adjuvant chemotherapy for breast cancer. Chin Med J. 2012;125:1862–6.PubMed Chen M, Zhan WW, Han BS, et al. Accuracy of physical examination, ultrasonography, and magnetic resonance imaging in predicting response to neo-adjuvant chemotherapy for breast cancer. Chin Med J. 2012;125:1862–6.PubMed
12.
go back to reference Curigliano G, Burstein HJ, Winer EP, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017. https://doi.org/10.1093/annonc/mdx308. Curigliano G, Burstein HJ, Winer EP, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017. https://​doi.​org/​10.​1093/​annonc/​mdx308.
13.
25.
go back to reference Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005. https://doi.org/10.1200/JCO.2005.07.032.CrossRefPubMed Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005. https://​doi.​org/​10.​1200/​JCO.​2005.​07.​032.CrossRefPubMed
26.
go back to reference Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER. Lancet. 2010. https://doi.org/10.1016/S0140-6736(09)61964-4.CrossRefPubMed Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER. Lancet. 2010. https://​doi.​org/​10.​1016/​S0140-6736(09)61964-4.CrossRefPubMed
30.
36.
Metadata
Title
Prediction of Pathologic Complete Response in Breast Cancer Patients Comparing Magnetic Resonance Imaging with Ultrasound in Neoadjuvant Setting
Authors
Frederik Knude Palshof
Charlotte Lanng
Niels Kroman
Cemil Benian
Ilse Vejborg
Anne Bak
Maj-Lis Talman
Eva Balslev
Tove Filtenborg Tvedskov
Publication date
01-11-2021
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 12/2021
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-021-10117-8

Other articles of this Issue 12/2021

Annals of Surgical Oncology 12/2021 Go to the issue